Myricx Bio Appoints New CEO, Expands Team in US and UK

What's Happening?

Myricx Bio, a private biotech company specializing in antibody-drug conjugates (ADCs), has appointed Mohit Rawat as its new CEO. Rawat, based in Boston, brings extensive experience in biopharma leadership and drug discovery. He previously served as President and Chief Business Officer at Fusion Pharmaceuticals, which was acquired by AstraZeneca. Myricx Bio is expanding its senior team across clinical, regulatory, and business development sectors in the US and UK. The company is focused on developing a novel class of ADC payloads, N-myristoyltransferase inhibitors (NMTi), to address payload resistance and improve tolerability in cancer therapy. Myricx Bio is preparing to enter clinical trials with its lead NMTi-ADC candidate, following a successful Series A financing round.

Why It's Important?

The appointment of Mohit Rawat as CEO marks a significant leadership transition for Myricx Bio, as the company aims to advance its innovative ADC therapies. ADCs are a transformative approach in cancer treatment, but challenges such as payload resistance and toxicity remain. Myricx Bio's focus on NMTi payloads offers a differentiated mode of action, potentially improving treatment outcomes for cancer patients. The expansion of the team in the US and UK reflects the company's growth ambitions and commitment to advancing its pipeline. This development could impact the biopharma industry by introducing novel therapeutic options and addressing unmet needs in oncology.

What's Next?

Myricx Bio plans to initiate human clinical trials for its lead NMTi-ADC candidate in 2026. The company is well-resourced to invest in its innovative platform and advance multiple ADC-NMTi programs through clinical development. The leadership succession and team expansion are expected to drive Myricx Bio's growth and enhance its capabilities in drug development. Stakeholders, including investors and the biopharma community, will be monitoring the company's progress and potential collaborations. The success of Myricx Bio's ADC therapies could influence future research and development strategies in the oncology field.